News

Quintiles Global Central Laboratories senior vice president Thomas Wollman said that through their alliance with London Genetics, they have expertise to help early adopters of personalised medicine use

The Phase II trial expects to recruit approximately 650 participants at some 30 health-care centers across the US Sanofi Pasteur’s, the vaccines division of Sanofi-aventis Group, Phase II

Mymetics already uses this new production method for its Respiratory Syncytial Virus (RSV) and Herpes Simplex Virus (HSV) vaccine that are in preclinical development. The patent, which describes

Perrigo has the exclusive rights from Synthon to sell and distribute the product in the US. Synthon claims that its product is the only approved generic product having

Built on the Microsoft SharePoint platform, the innovoPOINT solution enables clinical organisations to manage clinical information and processes for all clinical studies in a secure and compliant manner.

The neuroprotective efficacy of NK-102 is based on its dual mechanism of action. After a brain injury NK-102, firstly blocks neuronal apoptosis and also reduces inflammation by inhibiting

The updated product label, also called a package insert, includes bolded warnings and precautions that describe events that have been reported after Feraheme administration in the post-marketing environment,

In collaboration with Ark, the pre-clinical studies were partly funded by the Wellcome Trust, carried out by researchers at University College London (UCL) and the Rowett Institute of

Peginesatide is a novel investigational synthetic, PEGylated peptidic compound that binds to and activates the erythropoietin receptor and thus acts as an ESA. Affymax and Takeda are collaborating